うまく分類できないので、とりあえず書き付ける。
＜ongoing studies of osimertinib＞
・WJOG9717L: osimertinib+Bevacizumab, phase II
・TORG1833: osimertinib+Ramcirumab, phase II
・CheckMate-722: osimertinib+Nivolumab+Chemotherapy, phase III
・KEYNOTE-789: osimertinib+Pembrolizumab+Chemotherapy, phase III
＜Bevacizumab can prolong PFS, but not OS＞
・ECOG-ACRIN 5508 study
・AVAPERL
・POINT-BREAK
・WJOG5610L (COMPASS)
→How about WJOG11518L: CBDCA+PEM+Atezorizumab+Bevacizumab?
＜Pembrolizumab for Elderly＞
Nosaki et al., ELCC 2019
